This section does exactly that
Dipeptidyl dipeptidase-4 inhibitors These drugs, consisting primarily of sitagliptin, vildagliptin, linagliptin, saxagliptin, and alogliptin, enhance the effects of incretins by inhibiting dipeptidyl dipeptidase 4 (DPP-4), the enzyme responsible for their degradation
Ozempic triggers multiple physiological responses throughout the body, primarily affecting these systems: Insulin Secretion Enhancement : Stimulates pancreatic beta cells to release insulin in response to elevated blood glucose levels, providing glucose-dependent control that reduces hypoglycemia risk Glucagon Suppression : Reduces the release of glucagon from pancreatic alpha cells, preventing the liver from producing excess glucose during meals Gastric Emptying Delay : slows the rate at which food moves from the stomach to the small intestine, creating prolonged feelings of fullness Appetite Regulation : Acts on brain centers controlling hunger and satiety, reducing overall food intake and cravings Hepatic Glucose Production : Decreases the livers glucose output through both direct and indirect mechanisms The medication achieves its effects through once-weekly subcutaneous injections, with the FDA approving doses of 0.5 mg and 1.0 mg for diabetes management
Notably, the placebo group showed no statistically significant cholesterol level changes
What statistics support the effectiveness of organized weight loss initiatives
